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The accumulation of antibiotics in wastewater has led to the development and spreading of 
antibiotic resistance in the environment. Amoxicillin (Amox), a beta-lactamic antibiotic, is one 
of the most frequently consumed antibiotics in the world. We have applied two metal-organic 
frameworks (MOFs) containing zinc(II) as platforms to degrade Amox. We have predicted 
the adsorption of this antibiotic via molecular docking calculations which have been further 
corroborated by means of Fourier transform infrared and UV-Vis spectroscopies, thermogravimetric 
analysis, X-ray diffraction and scanning microscopy measurements. We have subsequently 
performed mass spectrometry analysis of Amox@zeolitic imidazolate framework-8 (ZIF-8) and 
Amox@Zn(1,4-benzenedicarboxylate) (ZnBDC) to demonstrate the degradation of Amox upon 
contact with the Zn-containing frameworks. We propose a possible pathway for the degradation of 
Amox involving the cleavage of the four-membered β-lactam ring. These Zn-containing frameworks 
provide a biocompatible platform for the degradation in solution of Amox, which should also be 
suitable to degrade other β-lactam antibiotics.
Keywords: β-lactamase activity, gentamicin, β-lactam catalysis, penicilloic and penilloic 
acids, biocompatible frameworks
Introduction
In the last decade, antibiotics have emerged as 
novel environmental pollutants. The widespread use of 
antibiotics in human and veterinary medicine, animal 
husbandry, plant production and aquaculture has led to high 
consumption and the gradual accumulation of antibiotics 
in the environment (e.g., wastewater, landfills, industrial 
and hospital effluents).1-6 From 100,000 to 200,000 t of 
antibiotics are consumed per year in hospitals, homes, 
veterinary use and aquaculture throughout the world.7 
On average, high-income countries generate ca. 0.5 kg 
of hazardous waste per bed per day whereas low-income 
countries generate ca. 0.2 kg. Furthermore, low-income 
countries do not separate hospital waste into hazardous 
or non-hazardous wastes, making the real quantity of 
hazardous waste much higher, as reported by the World 
Health Organization (WHO).
Environmental accumulation of antibiotics has 
raised serious concerns about the induction of antibiotic 
resistance.8-10 The exposure of bacteria to the subinhibitory 
antibiotic concentrations found in many natural 
environments such as sewage water and sludge, rivers, 
lakes and even drinking water is a crucial aspect of the 
current antibiotic resistance crisis.11-14 Furthermore, the 
incomplete absorption or metabolism of antibiotics in 
target organisms may lead to excretion rates from 5 to 
90% of the dose in the form of metabolites or as parent 
compounds.15,16 The chemical structure of antibiotics often 
contains cyclic moieties such as benzene rings, piperazine 
units, hexahydropyrimidines, sulfonamides, quinolone, 
and morpholine groups.5 Upon metabolic processing in 
humans and animals, these meta-stable compounds yield 
activated metabolites, which are continuously released in 
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the environment.4,17,18 The reactive properties of antibiotic-
derived metabolites are largely unknown, as well as the 
environmental impact of these compounds. Therefore, 
there is an urgent demand for the development of novel 
and efficient techniques to minimize water contamination 
by antibiotics.
Among the most efficient methods to remove 
pharmaceuticals in wastewater are carbon-activated 
adsorption-filtration,19,20 Fenton oxidation21,22 and 
photocatalytic degradation.23,24 However, these methods 
have some major drawbacks. The physical process using 
activated carbon and membrane filtration is limited to 
the transfer of antibiotics from one phase to another 
without dealing with its chemical degradation. Advanced 
oxidation technologies such as Fenton oxidation and 
photocatalytic degradation are often used for amoxicillin 
(Amox) degradation. However, a major problem of the 
process of the Fenton oxidation are the large volumes 
of iron sludge generated in the process, causing other 
environmental problems.21,25 Photocatalytic degradation 
has high operational cost and the photocatalytic reactions 
are generally slow compared to the rates of conventional 
chemical reactions, making it difficult to treat large volumes 
of wastewater.26,27 Therefore, new technologies are needed 
that can effectively remove antibiotics from the aquatic 
environment.
Metal-organic frameworks (MOFs) are infinite 
crystalline structures constructed by the self-assemblage 
of metal ions or clusters coordinated to multifunctional 
organic ligands. Depending on the resulting structure, the 
MOF skeleton can be flexible, combining a high cavity 
volume, regular crystallinity, and the presence of tunable 
organic groups within the framework.28 These properties 
provide more active adsorption sites and reaction centers29 
required for chemical degradation. Furthermore, MOFs can 
exhibit high biocompatibility and low toxicity depending on 
the choice of organic linkers and metal constituents. Several 
novel MOFs have also been developed for increased water 
stability.30 Some of these frameworks can endure water 
immersion for long periods of time in pH ranging from 0 
to 12.31 Therefore, MOFs have lately emerged as promising 
candidates for the treatment of wastewater.32
Amox is a stable acid, semi-synthetic drug within the 
penicillin class of β-lactam antibiotics widely used in both 
human and veterinary medicine to treat infections caused 
by Gram-positive or Gram-negative bacteria.33 Amox is 
chemically described as (2S,5R,6R)-6-[[(2R)-2-amino-
2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-
4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid.
Due to high consumption and continuous discharge, 
Amox has been detected in environmental samples at 
concentrations ranging between μg L-1-ng L-1.6,34 It has 
been further shown that subinhibitory concentrations of 
Amox can induce bacterial resistance in Escherichia coli, 
Listeria monocytogenes, Pseudomonas aeruginosa and 
Salmonella enterica.9 The biorefractory nature of Amox 
limits its effective removal in urban wastewater treatment 
plants through conventional treatment processes.35,36 Hence, 
the use of alternative treatment techniques resting upon 
the degradation of Amox into non-toxic intermediates is 
highly desirable. Several investigations have been reported 
in the literature using MOFs as agents for the degradation 
of Amox.37-39
In this report we describe the adsorption and degradation of 
Amox by the Zn-containing frameworks zeolitic imidazolate 
framework-8 (ZIF-8) and Zn(1,4-benzenedicarboxylate) 
(ZnBDC). We have initially performed molecular docking 
calculations to estimate the binding affinity40 of Amox for 
ZIF-8 and ZnBDC. We have further used gentamicin (Gen) 
as a negative control since our computational calculations 
predicted that this antibiotic does not bind to the ZIF-8 
and ZnBDC frameworks. The computationally predicted 
adsorption of Amox, but not Gen, to ZIF-8 and ZnBDC 
was confirmed by the means of Fourier transform infrared 
(FTIR) and UV-Vis spectroscopies, thermogravimetric 
analysis (TGA), X-ray diffraction (XRD) and scanning 
electron microscopy (SEM) measurements. We have further 
performed mass spectrometry (MS) analysis of Amox@ZIF-8 
and Amox@ZnBDC to demonstrate the degradation of 
Amox upon contact with the Zn-containing frameworks. 
Gen does not undergo any chemical transformation in 
presence of either ZIF-8 or ZnBDC. We assert that the Zn 
metal catalyzes the degradation of the beta-lactam ring in 
Amox, and propose a possible pathway for its degradation 
involving the cleavage of the four-membered β-lactam 
ring. Therefore, these Zn-containing frameworks provide 
a biocompatible platform for the degradation in solution 
of β-lactam antibiotics (e.g., penicillins, cephalosporins, 
cephamycins, carbapenems and monobactams), the most 
successful class of antibiotics developed so far.41
Experimental
Experimental procedure
All the reagents used were analytically pure unless 
stated otherwise. Solutions were prepared in purified water 
purified by the Milli-Q gradient Millipak® 40 system. Amox 
(≥ 900 μg per mg) and Gen sulfate salt (ca. 600 μg Gen 
per mg) were supplied by Aldrich. The other chemicals 
used were NaOH (Dinâmica), methanol (Dinâmica), 
Zn(NO3)2.6H2O (Vetec), benzenedicarboxylic acid 
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(Aldrich), KOH (Cinética), methanol (Dinâmica), formic 
acid (Vetec). ZIF-8 was acquired from Aldrich under the 
commercial name Basolite™ Z1200. The material was used 
without previous treatment. The procedure for the synthesis 
of the ZnBDC used in this work was developed in our group 
using previously published procedures.42,43 In a typical 
synthesis 0.056 g Na2BDC and 0.148 g Zn(NO3)2.6H2O 
were dissolved in 4 mL of water. The reactant mixture 
was placed in a 10 mL vessel, sealed and placed in a 
microwave oven (Discover, CEM) at 120 oC for 10 min, 
using a maximum power of 60 W. The solid result was 
filtered, washed with water and acetone to remove excess 
reactants, and finally dried in vacuum.
Diffractograms were recorded at room temperature 
in the range of 5 to 50o in a Rigaku 2400 DMAX XRD 
with Cu Kα (0.15 nm). TGA was performed in a 
Shimadzu DTG-60H instrument in the range from room 
temperature to 800 oC using an alumina crucible with about 
8.0 mg of sample, under dynamic nitrogen atmosphere 
(50 mL min-1) and with a heating rate of 10 oC min-1. The 
vibrational spectra in the infrared region (IR) were obtained 
Bruker IFS 66v/S FTIR spectrometer in the range of 
4000-400 cm-1. For SEM the samples were prepared on 
carbon tape on an aluminum support and coated with a 
10-20 nm gold film, using a Bal-Tec SCD 050 sputter 
coater. Images were recorded by an SEM (Jeol JSM-5900) 
operating at a voltage of 15 kV, a 4.0 probe and a working 
distance of 18 to 24 nm. The electrospray ionization mass 
spectrometry (ESI(+)-MS) were obtained using Micromass 
MS, in which samples were diluted in a solution of methanol 
and water (1:1) with 0.1% formic acid and analyzed by direct 
infusion; the flow used ranged from 10 to 30 μL min-1, in 
positive mode. The spray voltage, temperature, capillary 
voltage and other parameters were adjusted according to 
the sample in order to obtain a maximal response, using 
nitrogen as the drying gas. The acquisition of the MS was 
carried out 60 s after insertion. The spectra were acquired 
in the range 50-1000 m/z. In the experiments MS/MS, 
an ion of interest was selected and fragmented. The 
electronic absorption spectra in the UV and Vis regions of 
the obtained supernatants were performed for each system 
in a PerkinElmer Lambda 650 spectrophotometer, using 
deuterium and halogen lamps, scanning from 200 to 600 nm.
Drug loading was performed under stirring for 1, 3 and 
7 days of 100 mg of the framework (ZIF-8 or ZnBDC) in 
10 mL aqueous solution containing 300 mg of drug (Amox 
or Gen) as described by Horcajada et al.44 To the solution 
containing Amox it was added 1 mL of KOH (1 mol L-1) for 
the solubilization of the drug. After the incorporation period, 
the suspensions containing drug and MOF were subjected to 
the centrifugation process and drying under vacuum.
Computational details
Atomic coordinates for the ZnBDC and ZIF-8 
frameworks were taken from the Cambridge Structural 
Database (CSD1821299 and CSD602542, respectively). 
Molecular docking calculations were performed using the 
AutoDock 445-48 software combined with the AutoDock 
Tools.49 Partial charges for the receptor atoms were assigned 
according to AMBER86 force field parameters,50 while 
ligand charges were calculated with the Gasteiger method.51 
Dihedral angles were treated as fully flexible for ligands. 
Grid resolution and center were adjusted to each one of 
the systems. Grid maps of 126 × 126 × 126 points with 
point spacing of 1 Å were centered at the ZnBDC and 
ZIF-8 structures. The Lamarckian genetic algorithm (LGA) 
was used with the following parameters: 150 random 
individuals in an initial population, a maximum number 
of 2,500,000 energy evaluations, a maximum number of 
27,000 generations with mutation and crossover rates of 
0.02 and 0.08, respectively. An optional elitism parameter 
equal to 1 was applied, determining the number of top 
individuals that will survive into the next generation. 
A maximum of 300 iterations per local search was 
allowed. The probability of performing a local search 
on an individual was 0.06 where the maximum number 
of consecutive successes or failures before doubling or 
halving the search step was 4. A total of 100 LGA runs 
were performed. After the conformational search, docked 
conformations were sorted in the order of increasing 
energy. The coordinates of the lowest energy conformation 
were clustered based on a root-mean-squared-deviation 
(RMSD) of 2.0 Å.46-48 A more detailed description of the 
methodology employed has been previously presented.52,53 
Coordinates and trajectories were visualized with the 
software VMD version 1.9.1.54 The atomic coordinates for 
Amox and Gen were built and the geometry optimized with 
the software MarvinSketch 5.3.1.55
Results and Discussion
The adsorption or degradation of the drug was first 
assessed by visual inspection of coloration change during 
the formation of the complex. Amox in solution has a 
pallid orange color. Contact with ZnBDC and ZIF-8 
during the time period of up to 7 days changes the white 
color, characteristic of the MOFs, to brown (Figure S1, 
Supplementary Information (SI) section). Gen in contact 
with ZnBDC and ZIF-8 did not exhibit any alteration 
of color during the time period of up to 7 days. These 
results suggest that Amox is either incorporated into or 
degraded by the framework, whereas Gen may not have 
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been incorporated in the materials. In order to further 
investigate these findings, the drug-MOF systems were 
characterized by XRD (Figures S2-S7, SI section), SEM 
(Figure S8, SI section), TGA (Figures S9-S12, SI section), 
FTIR spectroscopy (Figures S13-S16, SI section), UV-Vis 
spectroscopy and MS. The supernatant was analyzed by 
MS and UV-Vis spectroscopy.
Molecular docking calculations
Molecular docking calculations were carried out to 
estimate the binding conformation and binding affinity of 
Amox and Gen onto the ZnBDC and ZIF-8 frameworks 
in different media (acidic or basic) conditions.28 Drug 
molecules were docked onto the framework structures 
and the lowest energy conformer was selected for each 
of the compounds tested (Figure 1). The lowest energy 
conformer is defined as the conformation of the ligand 
with the most favorable interaction energy as given 
by an empirical energy function48 and selected out of 
ca. 106 sampled conformations.47,52,53,56 Ideally, the lowest 
energy conformers should also belong to the most populated 
conformational cluster. This was the case for Amox based 
on an RMSD of 1.0 Å.
Amox adsorbs to both frameworks through electrostatic 
interactions between its carboxylate groups and the Zn2+ 
metals in the material surface (Figure 1). Depending on 
the protonation state of Amox, additional interactions with 
the Zn2+ metal are observed. Amox binds to the ZIF-8 and 
ZnBDC frameworks in a similar fashion under acidic and 
basic conditions (Figure 1). In basic medium, Amox binds to 
the framework surface by bridging two different Zn2+ atoms 
via electrostatic interactions to the thiazolidinic carboxylate 
and the deprotonated hydroxyl group (Figure 1). In acidic 
medium, Amox binds to a single Zn2+ atom through to the 
thiazolidinic carboxylate. In neutral conditions, Amox 
binds to two Zn2+ atoms via the thiazolidinic carboxylate 
and the β-lactam carbonyl groups in the case of ZIF-8, 
whereas in the ZnBDC it also binds to two Zn2+ atoms, but 
this time via the thiazolidinic carboxylate and the carbonyl 
from the acetoamido group (Figure 1). Based on the MS 
measurements for both systems (see below), both binding 
modes at neutral conditions allow the degradation of the 
antibiotic by the frameworks. The lowest energy Amox 
conformer in basic medium represents 99% (ZIF-8) or 
98% (ZnBDC) of the sampled conformations, whereas in 
neutral medium, it corresponds to 75% (ZIF-8) and 82% 
(ZnBDC), and at acidic medium, 65% (ZIF-8) and 78% 
(ZnBDC). These are merely a theoretical extrapolation 
since both frameworks are unstable in extreme media 
conditions. Estimated Amox binding affinity constants 
from the molecular docking calculations range between 
10-3 to 10-4 mol L-1 for ZIF-8, and 10-7 mol L-1 or higher for 
ZnBDC. Although these values should not be taken with 
caution due to the simplified potential energy function used 
in the molecular docking approach, it suggests that Amox 
adsorbs more strongly to ZnBDC than to ZIF-8.
Molecular docking calculations for Gen onto the 
ZnBDC and ZIF-8 frameworks did not result in any 
adsorbed conformation. Estimated affinity constants for 
this drug had positive values, indicative of unfavorable 
binding to both frameworks. These findings are consistent 
with the XRD and TGA measurements as discussed below.
X-Ray powder diffraction
Powder XRD was performed in order to examine the 
samples’ crystallographic phases qualitatively, as well as 
to evaluate possible alterations in the MOF structures after 
being exposed to the drugs. XRD patterns for Amox and 
Gen are presented in Figures S2 and S3 (SI section). The 
ZnBDC framework kept the same crystal structure before 
and after contact with the Gen solution for a time period 
of up to 7 days (Figure S4, SI section).28,57 Conversely, 
the XRD patterns for ZIF-8 before and after contact with 
Gen shows alterations (Figure S5, SI section), which may 
indicate drug adsorption to the framework (see further 
discussion of the TGA data below). The XRD patterns 
of the frameworks present thin peaks, indicating high 
crystallinity and in good agreement with previous studies 
reported in the literature.58,59 Conversely, the diffractograms 
obtained for ZnBDC show significant changes in peak 
Figure 1. Lowest energy conformers of Amox bound to (a-c) ZIF-8 and 
(d-f) ZnBDC under different (acidic, neutral or basic) media conditions 
emulated as different protonation states of the antibiotic. The respective 
lowest energy conformers are representative of the most populated 
conformational cluster. A total of 4.05 × 106 conformations were sampled 
for each one of the conformers.
Paula et al. 2131Vol. 29, No. 10, 2018
positions and relative intensities upon suspension in Amox 
solution for 1, 3 and 7 days (Figure S6, SI section). The 
XRD patterns for ZIF-8 show the same crystal structure 
after contact with Amox solution after 1, 3 and 7 days 
(Figure S7, SI section), pointing to change in the crystal 
structure of ZnBDC and ZIF-8 due to reaction with Amox. 
It has been previously shown by Rietveld refinement that 
ZnBDC exhibits one single phase before or after suspension 
in Gen solution, whereas it exhibits two or more crystal 
phases when suspended in Amox solution.28
Scanning electron microscopy
The morphology of the samples were evaluated 
qualitatively by SEM (Figure S8, SI section). The 
micrograph of ZnBDC shows crystals in small and large 
clusters with well-defined shapes and slightly deformed 
surfaces. The micrograph of commercial ZIF-8 shows 
crystalline particles in the nanometric regime, possibly due 
to fast nucleation during synthesis.60 Gen forms spherical 
particles of ca. 10 μm, whereas Amox forms spicules, some 
with large and elongated shapes and irregular length. The 
findings for Amox are in line with previous studies in the 
literature.61,62
Thermogravimetric analysis
The stability and thermal decomposition of the samples 
were evaluated by TGA in the presence and absence of the 
drugs (Figures S9-S12, SI section). The thermoanalytical 
profile of ZnBDC displays two steps. The first, in the region 
of 150 oC, can be interpreted as the loss of coordination water 
representing 14% of the total mass. The next step, between 
350 and 550 oC, corresponds to the thermal decomposition of 
the organic ligand and loss of 56% of the total mass. Similar 
results are reported in the literatrure.42 The thermoanalytical 
profile of ZIF-8 displays two events in the range of 350 
to 750 oC, which can be interpreted as mass loss of the 
imidazolate linker, which represents 70% of the total mass. 
The remaining mass corresponds to the compound ZnC, 
yielded after the loss of organic ligand. Similar results were 
previously reported by Ordoñez et al.60 The thermoanalytical 
profile of Gen shows loss of hydration water at about 100 oC, 
which corresponds to 10% of the total mass. The remaining 
mass corresponds to the decomposition of the Gen skeleton. 
The thermoanalytical profiles for Gen in the presence of 
ZnBDC exhibited a similar thermal behavior to that of the 
pure framework. The TGA profiles for ZIF-8 after suspension 
in the Gen solution feature loss of mass from both drug and 
framework (Figures S9-S12, SI section). These data indicate 
the drug adsorbs to the framework.
The thermoanalytical profile of Amox shows a loss of 
hydration water at the temperature range of 65 to 130 oC, 
which corresponds to a loss of 12% of the total mass. 
Additionally, three consecutive events are observed: 
the first event takes place in the range of 160 to 210 oC, 
with mass loss of 11%; the second event occurs in the 
interval of 211 to 320 oC, with mass loss of 26%; and the 
last one is observed in the range of 370 to 700 oC, which 
corresponds to 51% of total mass. These events can be 
interpreted as the decomposition of Amox, leading to the 
complete degradation of sample. The thermal analysis 
curve for the mixture Amox and ZnBDC shows four mass 
loss events whose profile is similar to the pure Amox 
thermal profile; likewise for the mixture Amox and ZIF-8. 
The first event is related to the loss of hydration water 
molecules trapped in the compound. The second event is 
attributed to the loss of the Amox and their degradation 
products. The third and fourth decomposition events 
correspond to the simultaneous thermal decomposition of 
Amox, their degradation products and ZnBDC, followed 
by carbonization of the material. In addition, the thermal 
stability of all samples was analyzed by comparing the 5% 
(T5) and 10% (T10) weight loss temperature of the samples 
(Table S1, SI section). In addition, residual mass at 700 oC 
is also reported.
Infrared spectroscopy
FTIR spectra were obtained for ZnBDC and ZIF-8 
before and after suspension in solutions of Gen and 
Amox for 1, 3 and 7 days (Figures S13-S16, SI section). 
The spectrum for ZnBDC exhibits one band centered 
at 3249 cm-1 attributed to O–H stretching due to water 
coordination. The strong absorption band at 1576 cm-1 is 
attributed to C=O stretching, which is displaced due to 
coordination with the metallic center. The FTIR spectrum 
for ZIF-8 exhibits small absorption bands at 3131 and 
2923 cm-1 related to the aromatic C–H stretching and the 
aliphatic C–H stretching in the imidazole, respectively. The 
band at 1605 cm-1 corresponds to the C=C stretching. The 
axial deformation of the C=N band occurs at 1576 cm-1, 
and the axial deformation of the C–N at 1145 cm-1. The 
absorption band at 421 cm-1 is associated with the stretching 
of the coordination Zn–N. Similar results are reported by 
Ordoñez et al.60 For Gen there is a band between 3500 
to 3250 cm-1 which corresponds to O–H stretching. In 
this interval, it is superposed to the band corresponding 
to N–H stretching. The bands at 1054 and 1112 cm-1 
correspond to the stretching of C–O and C–O–C absorption, 
respectively. Similar results are reported for streptomycin, 
which has similar vibrational modes to Gen.63 A few bands 
are observed for Amox corresponding to O–H and N–H 
axial deformation in the region of 3532 and 3450 cm-1, 
respectively. The C=O stretching β-lactam ring is quite 
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high due to the change in Amox molecular dipole moment 
produced by this mode of vibration64,65 at 1776 cm-1. The 
absorption at 1686 cm-1 is attributed to the C=O carbonyl 
group attached to the amide group. At 1483 cm-1 there is an 
overlay attributed to N–C stretch and angular deformation 
for the amide group. The FTIR spectra for ZnBDC and 
ZIF-8 in the presence of Gen do not exhibit significant 
changes during the period of 1, 3 and 7 days. On the other 
hand, both frameworks exhibit remarkable changes after 
suspension in the Amox solution. The FTIR spectrum 
for ZnBDC in the presence of Amox presents changes 
in chemical bonds. The characteristic vibrational modes 
related to asymmetric and symmetric C=O stretching 
in the ZnBDC framework occur at 1576 and 1366 cm-1, 
respectively (Figure S13, SI section).43 In the presence 
of Amox, the two main vibrational peaks (1576 and 
1145 cm-1) seen in the FTIR spectrum of ZIF-8 are no 
longer observed (Figure S16, SI section). The main peaks 
of the spectra for all samples is presented in Table S2 (SI 
section). It is most likely that these peaks underwent a 
shift and superposition with the bands associated with the 
Amox spectrum. The characteristic peak corresponding 
to C=O stretching in the β-lactam ring of Amox at 
1776 cm-1 is no longer observed in these spectra. The 
bands corresponding to the N–H stretching, amide C=O, 
carbonyl groups and aromatic rings in the interval 3500 to 
2600 cm-1 and to the C=C stretching at 1615 cm-1 can still 
be observed in the FTIR spectra. The intensity decrease 
or disappearance of these peaks indicates that Amox may 
undergo degradation in the presence of the frameworks 
(see discussion of the MS data).
UV-Vis spectroscopy
Absorption spectra in the UV-Vis region were obtained 
to investigate if Amox underwent degradation upon contact 
with the frameworks. The UV-Vis spectra were measured 
for the pure Amox as well as its mixtures with ZnBDC 
or ZIF-8 in the period of 1, 2 and 3 days (Figures 2 and 
3). The absorption spectrum for the pure Amox solution 
exhibits an electronic absorption band around 230 and 
272 nm.66,67 The band at 272 nm was used as reference 
to assure the structural conservation of Amox due to the 
higher sensitivity. Upon contact with the ZnBDC and ZIF-8 
frameworks, the absorption band shifts ca. 80 nm, i.e., from 
272 to 350 nm. The intensity ratio between the reference 
(272 nm) and the new band (350 nm) is significantly 
higher for ZIF-8 than for ZnBDC. The new adsorption 
band appears after 1 and 3 days in the presence of ZnBDC 
and ZIF-8, respectively. Therefore, the UV-Vis spectra 
show that Amox undergoes chemical degradation upon 
adsorption to the two Zn-containing frameworks.
Mass spectrometry
MS was used to detect the occurrence of degradation 
and detection of the resulting products in the supernatant 
and in the resulting solid after contact between frameworks 
and drugs.
The Amox MS revealed the presence of a peak 
corresponding to Amox at m/z 366 and its isotope at 
m/z 367 (Figure 4). A potassium adduct at m/z 404 and 
a fragment generated by the loss of ammonia at m/z 349 
were also observed.68 These assignments are consistent with 
MS measurements from Nägele and Moritz.69 The Amox 
dimer at m/z 731 with its respective isotope at m/z 732, and 
potassium adduct of these two peaks at m/z 769 and 770 
can also be observed in this spectrum. Similar behavior has 
been previously reported in literature.70
The MS for the solid phase of the sample containing 
Amox and frameworks shows the characteristic peak of 
Figure 2. UV-Vis spectra of pure Amox and mixed with ZnBDC for 1, 
3 and 7 days.
Figure 3. UV-Vis spectra of pure Amox and mixed with ZIF-8 for 1, 3 
and 7 days.
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Amox at m/z 366 (Figures 4 and 5). This peak is visible 
during the first 3 days of evaluation, disappearing after 
7 days. The peak at m/z 384 is attributed to penicilloic 
acid, and is present at 3 and 7 days (Figures 4 and 5).70,71 
The penicilloic acid is the degradation product formed by 
the opening of the β-lactam ring.70,71 The peak at m/z 340 
is attributed to the decarboxilation of the penicilloic acid, 
denominated peniloic acid.69,72 The same Amox degradation 
Figure 4. ESI(+)-MS of Amox and Amox-ZIF-8 (solid phase (Ds) and liquid (Dl)) at 3 and 7 days.
Figure 5. ESI(+)-MS of Amox and Amox-ZnBDC (solid phase (Ds) and liquid (Dl)) at 3 and 7 days.
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products observed for the solid phase of the samples of the 
frameworks are observed for the supernatant (Figure 6). 
The MS of the solid and supernatant samples exhibit a 
peak at m/z 297, which has not been previously identified 
as a degradation product of Amox in the absence of the 
frameworks (Figures 4 and 5). Its intensity increases with 
time, but the chemical structure of the compound associated 
with the peak at m/z 297 could not be determined at this 
point.
The MS data indicates that Gen does not undergo any 
chemical transformation in the presence of either ZIF-8 
or ZnBDC (Figure 6). The MS for Gen do not exhibit any 
significant modification for the samples containing only 
Gen or Gen in the presence of the frameworks (whether 
ZIF-8 or ZnBDC). The MS measurements for the solid 
phase of the samples containing only the frameworks do not 
show any indication of fragmentation of Gen, suggesting 
that this drug does not adsorb to these frameworks 
(Figures S17 and S18, SI section). MS measurements for 
ZnBDC and ZIF-8 are presented in Figure S19 (SI section).
Conclusions
The findings reported here are consistent with 
the degradation of Amox by both ZnBDC and ZIF-8 
frameworks. The degradation of Amox upon contact 
with the two MOFs is attributed to the presence of zinc 
ions, which is the catalytic agent in mono- and binuclear 
metallo-β-lactamases.73 Indeed, Zn2+ in this important class 
of enzymes is often tetracoordinated with imidazolate rings 
from histidine residues acting as ligands. These results are 
consistent with previous studies reporting on the role of 
Zn2+-containing materials in the degradation of antibiotics 
(Amox, ampicillin, penicillin-G, and penicillin-V) in 
aqueous solution and natural light exposure.74 These results 
evidence MOFs ZnBDC and ZIF-8 as new materials for 
Amox degradation. The products formed after degradation 
by the Zn-containing frameworks were penicilloic and 
penilloic acids, which are non-toxic.
Supplementary Information
Supplementary information is available free of charge 
at http://jbcs.sbq.org.br as PDF file.
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